Clinical Research Trials

DETERMINE-reduced- Dapagliflozin Effect on Exercise Capacity

An International, Multicenter, Parallel-group, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluation the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)

The purpose of this study is to answer the question of whether dapagliflozin can increase exercise capacity in patients with heart failure.

Principal Investigator: Dr. Harry Colfer

Contact: Study coordinator

Phone (Main): 231-487-3116

IRB Number: 2019-00035

Current Trial Type: 03877237

Status: Open to Enrollment